Vertex Pharmaceuticals has released clinical data for suzetrigine (VX-548), a novel non-opioid pain treatment. The drug met primary endpoints in acute pain trials but failed to outperform placebo in a study for sciatica. Despite the mixed results, Vertex is moving forward with regulatory submissions, positioning the molecule as a potential alternative to opioids.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.